Page 118 - journal-6-3-Full

Journal of Thai Traditional & Alternative Medicine Vol. 6 No. 3 September-December 2008 ÛÚ˜

∑ÿ°µ—«Õ¬à“ß∑”„Àâ°“√µÕ∫ πÕߢÕß∑’≈‘¡‚ø‰´µå≈¥≈ß ‡™àπ ¬—∫¬—Èß°“√‡®√‘≠¢Õ߇´≈≈å¡–‡√Á߉¥â.

‡À≈◊Շ撬ß√âÕ¬≈– Ò.Ù˘. ‡¡◊ËÕ°√–µÿâπ¥â«¬ “√ °—¥®“°‡ÀÁ¥ °“√µÕ∫ πÕߢÕß∑’≈‘¡‚ø‰´µå‚¥¬°“√ª√“°Ø¢Õß‚¡‡≈°ÿ≈
ªÕ√åÀ≈‘π®◊Õ “¬æ—π∏ÿå G5 ∑’ˉ¡à°–‡∑“–√à«¡°—∫ SEB ‡∑’¬∫ CD69 ∫πº‘«‡´≈≈åπ—Èπ “¡“√∂∑”„À⇰‘¥°“√µÕ∫ πÕßÕ◊Ëπ Ê
°—∫√âÕ¬≈– ÚÚ.Ò˜ ∑’Ë°√–µÿâπ¥â«¬ SEB ‡æ’¬ßÕ¬à“߇¥’¬« ·µà ¢Õß∑’≈‘¡‚ø‰´µåµ“¡¡“ ‚¥¬ CD69 ∑”Àπâ“∑’ˇªìπ costi-

¡’‡æ’¬ß ªÕ√å∑’ˉ¡à°–‡∑“–®“° “¬æ—π∏ÿå G9-1 ∑’Ë°√–µÿâπ√à«¡°—∫ mulatory molecule “¡“√∂°√–µÿâπ„Àâ ‡°‘¥°“√·∫àßµ—«¢Õß
Ò˜,Ò¯
SEB ‡∑à“π—Èπ ∑’ˉ¡àæ∫§«“¡·µ°µà“ß. ∑’≈‘¡‚ø‰´µå·≈–À≈—Ëß IL-2, TNF-α ·≈– IFN-γ πÕ°®“°
π’Ȭ—ß¡’°“√»÷°…“æ∫«à“ CD69 ¬—ß¡’∫∑∫“∑‡ªìπ
«‘®“√≥å
immunoregulatory molecule ‚¥¬¡’§«“¡ —¡æ—π∏å°—∫°“√
Ò˘
°“√»÷°…“§√—Èßπ’È ‰¥â∑”°“√∑¥ Õ∫ƒ∑∏‘Ï„π°“√°√–µÿâπ‡´≈≈å √â“ß transforming growth factor-β (TGF-β) ´÷Ë߇ªìπ
„π√–∫∫¿Ÿ¡‘§ÿâ¡°—π¢Õß “√ °—¥®“°‡ÀÁ¥À≈‘π®◊Õ “¬æ—π∏ÿåµà“ß Ê ‰´‚µ‰§πå∑’Ë¡’Àπâ“∑’˧«∫§ÿ¡°“√·∫à߇´≈≈å, °“√®”·π°™π‘¥,
∑—Èß∑’Ëπ”‡¢â“¡“®“°ª√–‡∑»®’πÀ√◊Õ¢¬“¬æ—π∏ÿå„πª√–‡∑» ‰¥â·°à °“√µ“¬·∫∫ apoptosis ¢Õ߇´≈≈å, ≈¥°“√ √â“ß proin-
ªÕ√å¢Õ߇ÀÁ¥À≈‘π®◊Õ “¬æ—π∏ÿå G2, G5 ·≈– G9 ∑—Èß·∫∫∑’Ë flammaory cytokines ´÷Ëß¡’§«“¡‡°’ˬ«‡π◊ËÕ߇ªìπÕ¬à“ß¡“°

°–‡∑“–·≈–‰¡à°–‡∑“– ‚¥¬°“√„™â‡∑§π‘§∑“ß‚ø≈‰´‚µ‡¡∑√’ °—∫°≈«‘∏“πµâ“π¡–‡√Áß.
‚¥¬°“√«—¥°“√ª√“°Ø¢Õß‚¡‡≈°ÿ≈ CD69 ´÷Ë߇ªìπ early acti- ‚¥¬¢âÕ¡Ÿ≈∑’˧âπæ∫„π°“√»÷°…“§√—Èßπ’ȇªìπ¢âÕ¡Ÿ≈‡∫◊ÈÕßµâπ

vation marker ∑’Ë®–ª√“°Ø¢÷Èπ∫πº‘«¢Õß∑’≈‘¡‚ø‰´µå, ∑’Ë®– “¡“√∂π”¡“„™âª√–°Õ∫°“√µ—¥ ‘π„®„π°“√§—¥‡≈◊Õ°À√◊Õ
∫’≈‘¡‚ø‰´µå, ‡ÕÁπ‡§‡´≈≈å, π‘«‚∑√øî≈ À≈—ß∂Ÿ°°√–µÿâπ‡æ’¬ß Ú- ª√—∫ª√ÿß “¬æ—π∏ÿå·≈–æ—≤π“°“√π”‡ÀÁ¥À≈‘π®◊Õ·≈– ªÕ√å‡ÀÁ¥
Û ™—Ë«‚¡ß ´÷Ëß “¡“√∂„™â∑¥ Õ∫°“√µÕ∫ πÕߢÕ߇´≈≈凡Á¥ À≈‘π®◊Õ„πª√–‡∑»‰∑¬‰ª„™âª√–‚¬™πåµàÕ‰ª‰¥â.
ÒÛ
‡≈◊Õ¥¢“«µà“ß Ê ∑’Ë¡’µàÕ “√°√–µÿâπ‰¥â .
°‘µµ‘°√√¡ª√–°“»
®“°º≈°“√»÷°…“æ∫«à“ “√ °—¥πÈ”·≈– à«π∑’ˉ¡à≈–≈“¬„π
πÈ”®“° ªÕ√å¢Õ߇ÀÁ¥À≈‘π®◊Õ “¬æ—π∏ÿå G9 ∑’ˉ¡à°–‡∑“– ´÷Ëß °“√»÷°…“„π§√—Èßπ’ȉ¥â√—∫∑ÿπ π—∫ πÿπ®“° ∂“∫—π°“√

‡ªì𠓬æ—π∏ÿå∑’Ë¡“®“°ª√–‡∑»®’ππ—Èπ “¡“√∂°√–µÿâπ„À⇰‘¥ ·æ∑¬å‰∑¬-®’π ‡Õ‡™’¬µ–«—πÕÕ°‡©’¬ß„µâ °√¡æ—≤π“°“√
°“√µÕ∫ πÕߢÕß∑’≈‘¡‚ø‰´µå‰¥â¥’∑’Ë ÿ¥ „π¢≥–∑’Ë “¬æ—π∏ÿå G2 ·æ∑¬å·ºπ‰∑¬·≈–°“√·æ∑¬å∑“߇≈◊Õ° °√–∑√«ß “∏“√≥ ÿ¢
´÷Ë߇ªì𠓬æ—π∏ÿå∑’Ëπ”¡“‡æ“–‡≈’Ȭ߷≈–¢¬“¬æ—π∏ÿå„πª√–‡∑» ·≈– ”π—°ß“π§≥–°√√¡°“√«‘®—¬·Ààß™“µ‘. §ÿ≥∫ÿ≠„® ≈‘Ë¡»‘≈“

‰∑¬π—Èπ æ∫«à“ “¡“√∂°√–µÿâπ„À⇰‘¥°“√µÕ∫ πÕ߉¥â‡æ’¬ß ·≈–∑’¡ß“𠉥â™à«¬‡À≈◊Õª√– “πß“πµà“ß Ê ‡ªìπÕ¬à“ߥ’.
ª√–¡“≥§√÷ËßÀπ÷Ë߇∑à“π—Èπ‡¡◊ËÕ‡∑’¬∫°—∫ “¬æ—π∏ÿå G9 ( “√ °—¥πÈ”:

ÒÒ.¯˜% (G2) ‡∑’¬∫°—∫ Úˆ.ÚÒ %(G9), “√‰¡à≈–≈“¬„ππÈ”:
Ù.ıı% (G2) ‡∑’¬∫°—∫ ¯.Òˆ % (G9)).
®“°°“√«‘‡§√“–Àå “√ ”§—≠„π “√ °—¥®“°‡ÀÁ¥À≈‘π ‡Õ° “√Õâ“ßÕ‘ß

®◊Õ “¬æ—π∏ÿåµà“ß Ê æ∫«à“¡’æÕ≈‘·´Á°§“‰√¥å‡ªìπ à«πª√–°Õ∫ Ò. Yue GGL, Fung K, Leung P, Lau CBS. Comparative studies on the
immunomodulatory and antitumor activities of the different parts of
¯,ÒÙ
´÷Ëßµ√ß°—∫º≈°“√«‘®—¬Õ◊Ëπ Ê °àÕπÀπâ“π’È ‚¥¬æÕ≈‘·´Á°§“-
fruiting body of Ganoderma lucidum and Ganoderma spores. Phytother
‰√¥å´÷Ë߉¥â®“° “√ °—¥πÈ”π—Èπ ¡’ƒ∑∏‘Ï„π°“√°√–µÿâπ¿Ÿ¡‘§ÿâ¡°—π Res 2008;22:1282-91.
Ú. Muller C, Kumagai T, OûKelly J, Seeram NP, Heber D, Koeffler HP.
“¡“√∂°√–µÿâπ°“√ √â“ß IL-10, TNF-α, IL-1β, IL-6 ·≈– IL-
Ganoderma lucidum causes apoptosis in leukemia, lymphoma and
Òı
2 ®“°‚¡‚π𑫇§≈’¬‡´≈≈å °√–µÿâπ°“√·∫àßµ—«·≈–°“√ √â“ß IL- multiple myeloma cells. Leuk Res 2006;30:841-8.
Òˆ Û. Hong KJ, Dunn DM, Shen CL, Pence BC. Effects of Ganoderma
1, IL-2 ·≈– IFN-γ ®“°‡´≈≈å¡â“¡ÀπŸ ´÷Ë߃∑∏‘Ï°“√°√–µÿâπ
lucidum on apoptotic and anti-inflammatory function in HT-29 human
¿Ÿ¡‘§ÿâ¡°—ππ’Ȭ—߇°’ˬ«‡π◊ËÕ߉ª∂÷߃∑∏‘Ï„π°“√µâ“π¡–‡√ÁߢÕß “√ colonic carcinoma cells. Phytother Res 2004;18:768-80.
Ù. Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D. Ganoderma
°—¥®“°‡ÀÁ¥À≈‘π®◊Õ ‚¥¬‡ªìπº≈¡“®“°‰´‚µ‰§πåµà“ß Ê ∑’Ë∂Ÿ°
lucidum suppresses growth of breast cancer cells through the inhibition
√â“ߢ÷È𠇙àπ IL-1β, IL-6, TNF-α ·≈– IFN-γ ´÷Ëß “¡“√∂ of Akt/NF-kappaB signaling. Nutr Cancer 2004;49:209-16.